Clinical Neuropsychologist Online
  • Clinical Neuropsychologist
    • Neuropsychological Assessment
      • What is Clinical Neuropsychology?
      • Our Clinical Neuropsychology Consults
        • Post-COVID Neuropsychological Assessment
    • Our Clinical Neuropsychologist
      • Clinical Neuropsychologist Referral
      • Clinical Neuropsychology Intake Upload
    • Clinical Neuropsychologist Online Appointments
      • Intake Appointment
      • Neuropsychologist Consult
      • Neuropsychology Feedback Session
  • Neuropsychology Knowledgebase
    • Acquired Brain Injury
    • Alzheimer’s Disease Neuropsychology
    • COVID-19 Neuropsychology
    • Dementia Neuropsychology
    • Memory Neuropsychology
    • Neuroanatomy & Neuroradiology
    • Neuropsychological Assessment
    • Neuropsychological Disorders
    • Psychometrics in Neuropsychology
  • Neuropsychology CPD
    • Latest Journal Articles
    • Cognitive Neuropsychology
    • Dementia
    • Neuro Podcasts
    • Neuroimaging
    • Neuropsychology (general)
    • Neurorehabilitation
    • Neuroscience
    • Paediatric Neuropsychology
  • Neuropsychology Courses
  • Newsletter
  • Brain Lounge
Select Page

The contribution of cerebral small vessel disease in idiopathic normal pressure hydrocephalus: Insights from a prospective cohort study

by Clinical Neuropsychologist | Friday, November 22, 2024 | Dementia

Abstract INTRODUCTION Idiopathic normal pressure hydrocephalus (iNPH) and cerebral small vessel disease (CVSD) are age-related diseases, but their prevalence and clinical relationship are unclear. METHODS This prospective cohort study enrolled 95 patients with...

Benchmarking of a multi‐biomarker low‐volume panel for Alzheimer’s disease and related dementia research

by Clinical Neuropsychologist | Friday, November 22, 2024 | Dementia

Abstract INTRODUCTION In the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer’s disease (AD), but no platform can measure all the...

Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid‐positive early Alzheimer’s disease

by Clinical Neuropsychologist | Friday, November 22, 2024 | Dementia

Abstract BACKGROUND This study examines whether phosphorylated plasma Tau217 ratio (pTau217R) can predict tau accumulation in different brain regions, as measured by positron emission tomography (PET) standardized uptake value ratio (SUVR), for staging...

APOE ε4–associated heterogeneity of neuroimaging biomarkers across the Alzheimer’s disease continuum

by Clinical Neuropsychologist | Friday, November 22, 2024 | Dementia

Abstract INTRODUCTION While the role of apolipoprotein E (APOE) ε4 in Alzheimer’s disease (AD) susceptibility has been studied extensively, much less is known about the differences in disease presentation in APOE ε4 carriers versus non-carriers. METHODS To help...

Biological validation of peak‐width of skeletonized mean diffusivity as a VCID biomarker: The MarkVCID Consortium

by Clinical Neuropsychologist | Thursday, November 21, 2024 | Dementia

Abstract BACKGROUND Peak-width of skeletonized mean diffusivity (PSMD), a neuroimaging marker of cerebral small vessel disease (SVD), has shown excellent instrumental properties. Here, we extend our work to perform a biological validation of PSMD. METHODS We included...
« Older Entries
Next Entries »

Posts by Category

  • Cognitive Neuropsychology
  • Dementia
  • Neuro Podcasts
  • Neuroimaging
  • Neuropsychology (general)
  • Neurorehabilitation
  • Neuroscience
  • Paediatric Neuropsychology

Neuropsychology Newsletter &
Interest List

S U B S C R I B E

  • X
  • RSS
© PsyAsia Neuropsychology. Clinical Neuropsychologist Hong Kong & Online. Part of the Psychology1 Group. All Rights Reserved.
DISCLAIMER: We are not responsible for any inaccuracies at this site. No medical advice is being offered to you personally.
No medical contract is formed by you visiting PsyAsia Neuropsychology.